Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 10/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HSD11B2 | P80365 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19808239 | 1.00 | EPHX2 (0.40) | EPHX2HSD11B1ALDH1A1LMNAHSD11B2 | |
| SCHEMBL20724768 | 1.00 | EPHX2 (0.40) | EPHX2HSD11B1ALDH1A1LMNAHSD11B2 | |
| SCHEMBL19798458 | 0.86 | EPHX2 (0.51) | EPHX2ALDH1A1LMNAKMT2AFAAH | |
| SCHEMBL19798456 | 0.86 | EPHX2 (0.51) | EPHX2ALDH1A1LMNAKMT2AFAAH | |
| SCHEMBL19798454 | 0.86 | EPHX2 (0.51) | EPHX2ALDH1A1LMNAKMT2AFAAH | |
| SCHEMBL20724781 | 0.81 | CA12 (0.31) | ALDH1A1LMNA | |
| SCHEMBL19808587 | 0.80 | LMNA (0.51) | EPHX2HSD11B1ALDH1A1LMNAHSD11B2 | |
| SCHEMBL20724759 | 0.78 | EPHX2 (0.39) | EPHX2HSD11B1ALDH1A1LMNAHSD11B2 | |
| SCHEMBL19808244 | 0.78 | HSD11B1 (0.40) | EPHX2HSD11B1ALDH1A1LMNAHSD11B2 | |
| SCHEMBL19798650 | 0.77 | EPHX2 (0.38) | EPHX2HSD11B1ALDH1A1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202388-B2 | Fused-ring compounds, pharmaceutical composition and uses thereof | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2019-02-12 | — | — | US | disclosed |
| US-20180022752-A1 | FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202388-B2 | Fused-ring compounds, pharmaceutical composition and uses thereof | IDO1, IDO2, TDO2 | EPHX2 1124/4885HSD11B1 196/4885ALDH1A1 2128/4885 |
| US-20180022752-A1 | FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF | IDO1, IDO2, TDO2 | EPHX2 1124/4885HSD11B1 196/4885ALDH1A1 2128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.